Amylyx Pharmaceuticals
AMLX
131 hedge funds and large institutions have $524M invested in Amylyx Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 37 increasing their positions, 37 reducing their positions, and 36 closing their positions.
1,338% more call options, than puts
Call options by funds: $1.48M | Put options by funds: $103K
500% more funds holding in top 10
Funds holding in top 10: 1 → 6 (+5)
100% more capital invested
Capital invested by funds: $262M → $524M (+$262M)
8.24% more ownership
Funds ownership: 83.41% → 91.64% (+8.2%)
0% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 37
4% less funds holding
Funds holding: 136 → 131 (-5)
14% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 36
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$17.6M |
| 2 |
BlackRock
New York
|
+$15.2M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$15.1M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$9.19M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$6.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Aberdeen Group
Edinburgh,
United Kingdom
|
-$8.23M |
| 2 |
Millennium Management
New York
|
-$7.64M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$7.37M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$6.62M |
| 5 |
Goldman Sachs
New York
|
-$3.43M |
AMLX Hedge Fund Activity: Q2 2025 in Review
131 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q2 2025, worth a combined $524M — up 100% from $262M a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of AMLX and 31 opened new positions — a net loss of 5 holders — while 37 trimmed existing stakes and 37 added.
The largest buyer was Point72 Asset Management, adding an estimated $17.6M. The largest seller was Aberdeen Group, cutting an estimated $8.23M.
- 131 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q2 2025, down from 136 in Q1 2025.
- Funds reported $524M of Amylyx Pharmaceuticals stock for Q2 2025, up 100% quarter-over-quarter.
- 31 funds opened new Amylyx Pharmaceuticals positions in Q2 2025 and 36 closed out, a net change of -5 holders.
- The largest Amylyx Pharmaceuticals buyer in Q2 2025 was Point72 Asset Management, an estimated $17.6M added.
- The largest Amylyx Pharmaceuticals seller in Q2 2025 was Aberdeen Group, an estimated $8.23M sold.
Based on aggregated 13F filings for Q2 2025.